Naomi Haas, MD, discusses the importance of using PSMA, an antigen that is expressed on the cell surface, for the detection of prostate cancer.
Naomi Haas, MD, director, Prostate and Kidney Cancer Program, associate professor, Medicine, Hospital of the University of Pennsylvania, discusses the importance of using PSMA, an antigen that is expressed on the cell surface, for the detection of prostate cancer.
PSMA is widely expressed in prostate tissue in cancer, and it isn’t well expressed in normal tissue, Haas says. For that reason, PSMA is a good target because there aren’t as many toxicity concerns with it.
In normal tissue, PSMA is part of the neurotransmission of things, and in intestinal tissue, it helps with folate transfer. People aren’t sure what its function is in prostate tissue, says Haas. However, it an area of important interest at this time based on its high level of expression in prostate cancer.
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More